Fixed Dose Combination of Pramipexole and Rasagiline for Parkinson's
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Parkinson's disease, particularly dopamine agonists like pramipexole and rasagiline, are limited by severe adverse events such as nausea, vomiting, orthostatic hypotension, and impulse control disorders, necessitating complex titration schedules and higher doses that increase risk, while rasagiline has safety concerns with tyramine-rich foods and SSRIs.
Innovation Solution
A fixed dose combination of pramipexole and rasagiline in a ratio of 0.05 mg to 1.0 mg, with pramipexole at a lower dose than rasagiline, formulated for extended release to minimize adverse events and maintain efficacy, using a combination of inert pellets, sub-coating, and extended-release coating layers for controlled release over 24 hours.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If higher doses of dopamine agonists are used to improve therapeutic efficacy, then anti-Parkinsonian effect is enhanced, but adverse events such as nausea, vomiting, orthostatic hypotension, and impulse control disorders increase in severity and frequency
Solution Approach 1:
The patent divides the therapeutic approach into two separate agents with different mechanisms of action: a dopamine agonist (pramipexole) and an MAO-B inhibitor (rasagiline). Each agent is administered at lower doses than would be required for monotherapy, but together they provide synergistic therapeutic effect while reducing the adverse events associated with high-dose dopamine agonist monotherapy
Solution Approach 2:
The patent creates a composite therapeutic regimen combining two pharmacologically distinct agents (dopamine agonist and MAO-B inhibitor) that work through complementary mechanisms. This composite approach allows for enhanced anti-Parkinsonian efficacy at lower individual doses, thereby minimizing the harmful effects associated with higher doses of either agent alone
2Object-generated harmful factors
If a slow and complex titration schedule is implemented to mitigate side effects, then adverse events are reduced, but treatment complexity and time required to achieve therapeutic effect increase
Solution Approach 1:
The patent separates the therapeutic functions into two agents with different side effect profiles and mechanisms of action. The MAO-B inhibitor (rasagiline) has a favorable side effect profile and can be used to provide baseline therapy, allowing the dopamine agonist to be introduced at lower doses with reduced risk of adverse events, thereby simplifying the overall titration process
Solution Approach 2:
The patent changes the dosing parameters by using lower doses of the dopamine agonist in combination with an MAO-B inhibitor. This parameter change allows for a simplified titration schedule because the combination therapy achieves therapeutic effect at lower dopamine agonist doses, reducing the need for complex gradual dose escalation
3Object-generated harmful factors
If low doses of dopamine agonists are used to minimize adverse events, then safety is improved, but therapeutic efficacy is insufficient when used alone
Solution Approach 1:
The patent merges two pharmacologically distinct agents: a dopamine agonist (pramipexole) and an MAO-B inhibitor (rasagiline). The dopamine agonist provides direct dopaminergic stimulation while the MAO-B inhibitor prevents dopamine breakdown and has additional neuroprotective effects. This merging allows for enhanced therapeutic efficacy at lower doses of the dopamine agonist, thereby maintaining safety while improving effectiveness
Solution Approach 2:
The patent creates a composite therapeutic system combining two agents with complementary mechanisms of action. The dopamine agonist addresses immediate symptomatic control while the MAO-B inhibitor provides sustained dopamine availability and potential neuroprotection. This composite approach achieves adequate therapeutic efficacy at lower dopamine agonist doses, minimizing adverse events while maintaining treatment effectiveness
4Adaptability or versatility
If rasagiline is used in combination with SSRIs and other antidepressants, then depression treatment is provided, but serotonin reaction and hypertensive crisis risk increase
Solution Approach 1:
The patent applies preliminary anti-action by selecting an MAO-B inhibitor (rasagiline) with selective inhibition of the B isoenzyme, which has a lower risk of interaction with SSRIs and antidepressants compared to non-selective MAO inhibitors. This selective inhibition approach preemptively reduces the risk of serotonin reaction and hypertensive crisis while still providing therapeutic benefit for Parkinson's disease and comorbid depression
Data Source
AI summary
A pharmaceutical composition for use in treatment of Parkinson's disease is provided comprising a pharmaceutically acceptable carrier and a fixed dose combination of pramipexole and rasagiline, wherein the fixed dose combination contains a subtherapeutic dose of pramipexole and a subtherapeutic dose of rasagiline, and the dose of pramipexole is lower than or equal to the dose of rasagiline.